戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1            Several other disorders can mimic polymyalgia rheumatica.
2 h as muscle pains and stiffness diagnosed as polymyalgia rheumatica.
3 e for patients with glucocorticoid-dependent polymyalgia rheumatica.
4 lying therapeutic innovations to people with polymyalgia rheumatica.
5 atients with active glucocorticoid-dependent polymyalgia rheumatica.
6 ases, infections, and malignancies can mimic polymyalgia rheumatica.
7 may be clinically useful in the treatment of polymyalgia rheumatica.
8 ases in acute phase reactants are typical of polymyalgia rheumatica.
9 GCA relapse heralded by symptoms of isolated polymyalgia rheumatica (1 case versus 5 in the placebo g
10 timate of 21 million for 1995), 711,000 have polymyalgia rheumatica, 228,000 have giant cell arteriti
11 n criteria were persistent disease activity (polymyalgia rheumatica activity score computed using the
12 ed to identify the pathological substrate of polymyalgia rheumatica and it is increasingly used to su
13  6 other AIDs; both shared associations with polymyalgia rheumatica and rheumatoid arthritis.
14 toms and clinical features characteristic of polymyalgia rheumatica and/or giant cell arteritis (GCA)
15 ence interval [CI] 1.64-1.84; range 1.52 for polymyalgia rheumatica and/or giant cell arteritis to 2.
16              Participants were patients with polymyalgia rheumatica and/or giant cell arteritis who w
17 nifestations are headache, jaw claudication, polymyalgia rheumatica, and visual symptoms.
18 ed clinical trial enrolled 101 patients with polymyalgia rheumatica at 17 hospitals in France from Fe
19 medical record review: rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, psor
20 d as the resolution of signs and symptoms of polymyalgia rheumatica by week 12 and sustained normaliz
21                   Among patients with active polymyalgia rheumatica despite prednisone therapy, tocil
22                                     Although polymyalgia rheumatica does not clearly impair survival
23 corticoid dose in patients with a relapse of polymyalgia rheumatica during glucocorticoid tapering.
24   This issue provides a clinical overview of polymyalgia rheumatica, focusing on risk factors, diagno
25              More than half of patients with polymyalgia rheumatica have a relapse during tapering of
26     Individuals with prior diagnoses of GCA, polymyalgia rheumatica, HIV, or transplant status were e
27                                              Polymyalgia rheumatica is a chronic, inflammatory disord
28                                              Polymyalgia rheumatica is an inflammatory disease produc
29                                              Polymyalgia rheumatica is an inflammatory disease that a
30 94 patients with giant cell arteritis and/or polymyalgia rheumatica (n = 25,581), inflammatory bowel
31 val (CI): 1.1-1.2), P=9.8 x 10(-11)) and for polymyalgia rheumatica near C6orf10 at rs6910071 (OR=1.5
32                                              Polymyalgia rheumatica occurred with similar frequency i
33 s cross-sectional study of 267 patients with polymyalgia rheumatica or giant cell arteritis found a G
34                                              Polymyalgia rheumatica (PMR) and giant cell arteritis (G
35               Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely related conditi
36                                              Polymyalgia rheumatica (PMR) has an abrupt onset of infl
37 omic basis for joint disease localization in polymyalgia rheumatica (PMR) is poorly understood.
38                                              Polymyalgia rheumatica (PMR) is the second most common i
39                    To evaluate the impact of polymyalgia rheumatica (PMR) on clinical outcomes and qu
40                   Imaging studies in GCA and polymyalgia rheumatica (PMR) suggest that vasculitis can
41                 GCA frequently overlaps with polymyalgia rheumatica (PMR), a rheumatic inflammatory c
42                             In patients with polymyalgia rheumatica (PMR), a subclinical variant of G
43 /or visual abnormalities, fever, concomitant polymyalgia rheumatica (PMR), and histologic evidence of
44 nifestations are headache, jaw claudication, polymyalgia rheumatica (PMR), and visual symptoms, but 4
45 ic lupus erythematosus, psoriatic arthritis, polymyalgia rheumatica (PMR), giant cell arteritis, anky
46  of Rheumatology classification criteria for polymyalgia rheumatica (PMR).
47 ous cardiovascular diseases in patients with polymyalgia rheumatica (PMR).
48 such as anti-interleukin 6, in patients with polymyalgia rheumatica that is refractory to glucocortic
49                             One patient with polymyalgia rheumatica who developed the inhibitor while
50 with nonstenosing vasculitis; and "isolated" polymyalgia rheumatica with myalgias, systemic inflammat